von Tresckow, Julia
Cramer, Paula
Bahlo, Jasmin
Robrecht, Sandra
Langerbeins, Petra
Fink, Anna-Maria
Al-Sawaf, Othman http://orcid.org/0000-0001-9895-0570
Illmer, Thomas
Klaproth, Holger
Estenfelder, Sven
Ritgen, Matthias
Fischer, Kirsten
Wendtner, Clemens-Martin
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Böttcher, Sebastian
Eichhorst, Barbara F.
Hallek, Michael
Article History
Received: 7 November 2018
Accepted: 14 November 2018
First Online: 19 December 2018
Compliance with ethical standards
:
: JvT: Research funding (F. Hoffmann-LaRoche, Janssen-Cilag), honoraria and consultant or advisory board member (AbbVie, Janssen-Cilag and F. Hoffmann-LaRoche), travel grants (AbbVie, Celgene, F. Hoffmann-LaRoche and Janssen-Cilag). PC: Research funding (AbbVie, Gilead, GlaxoSmithKline/Novartis, F. Hoffmann-LaRoche, and Janssen-Cilag), honoraria (F. Hoffmann-LaRoche and Janssen-Cilag), consultant or advisory board member (AbbVie, AstraZeneca, Janssen-Cilag and Novartis) and travel grants (Astellas, F. Hoffmann LaRoche, Gilead, Janssen-Cilag and Mundipharma). JB: Honoraria and travel grants (F. Hoffmann-LaRoche). PL: Research funding (Janssen-Cilag), Honoraria (AbbVie, Janssen-Cilag and F. Hoffmann-LaRoche), travel grants (AbbVie, F. Hoffmann-LaRoche, Janssen-Cilag and Mundipharma) AF: Research funding (Celgene), honoraria (F. Hoffman-LaRoche) and travel grants (F. Hoffmann-LaRoche, Mundipharma, Abbvie and Celgene). OA: Honoraria and consultant or advisory board member (AbbVie, Gilead and F. Hoffmann-LaRoche), travel grants (AbbVie, Gilead, F. Hoffmann-LaRoche and Janssen-Cilag). TI: Travel grants (F. Hoffmann-LaRoche). MR: Research funding (AbbVie; F. Hoffmann-LaRoche), consultant or advisory board member (AbbVie, BMS, F. Hoffmann-LaRoche) and travel grants (F. Hoffmann-LaRoche). KF: Travels grants (F. Hoffmann-LaRoche). CMW: Honoraria, consultant or advisory board member, research funding and travel grants (AbbVie, Gilead, F. Hoffmann-LaRoche, Janssen-Cilag and Mundipharma). KK: Research funding, honoraria, consultant or advisory board member and speaker´s bureau (F. Hoffmann-LaRoche, Janssen-Cilag and Mundipharma). SS: Research support, honoraria, consultant or advisory board member, speaker´s bureau and travel support (AbbVie, Amgen, Astra-Zeneca, Celgene, F. Hoffmann-LaRoche, Gilead, GlaxoSmithKline, Janssen-Cilag and Novartis). SB: Reasearch funding (AbbVie, Celgene and F. Hoffmann-LaRoche), honoraria (AbbVie, Becton Dickinson, F. Hoffmann-LaRoche), consultant or advisory board member (F. Hoffmann-LaRoche), travel grants (Celgene, F. Hoffmann-LaRoche). BE: Research support, consultant or advisory board member and travel support (AbbVie, Celgene, F. Hoffmann-LaRoche, Gilead, GlaxoSmithKline, Janssen-Cilag, Mundipharma). MH: Research funding (AbbVie, Celgene, F. Hoffmann-LaRoche, Gilead, Janssen-Cilag, Mundipharma and Pharmacyclics), honoraria and speaker´s bureau (AbbVie, Boehringer-Ingelheim, Celgene, F. Hoffmann-LaRoche, Gilead, Janssen-Cilag, Mundipharma and Pharmacyclics) and consultant or advisory board member (AbbVie, F. Hoffmann-LaRoche, Gilead, Janssen-Cilag). The remaining authors declare that they have no conflict of interest.